CANbridge Sponsors Gene Therapy Research for Duchenne Muscular Dystrophy
publication date: Nov 4, 2021
CANbridge, a Beijing rare disease biopharma, announced a two-year sponsored gene therapy research agreement for Duchenne muscular dystrophy, a rare childhood neuromuscular disease. CANbridge will fund research at the University of Washington in Seattle that will be directed by Jeffrey Chamberlain, PhD, professor in the Departments of Neurology, Medicine and Biochemistry. Dr. Chamberlain is well-known for his research into the use of gene therapies for muscle diseases. In particular, his lab has been studying muscular dystrophy mechanisms, including dystrophin structure, and gene therapy approaches. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.